329 related articles for article (PubMed ID: 16787302)
1. Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase.
Koch U; Narjes F
Infect Disord Drug Targets; 2006 Mar; 6(1):31-41. PubMed ID: 16787302
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.
Koch U; Narjes F
Curr Top Med Chem; 2007; 7(13):1302-29. PubMed ID: 17627559
[TBL] [Abstract][Full Text] [Related]
3. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections.
Beaulieu PL
Curr Opin Investig Drugs; 2007 Aug; 8(8):614-34. PubMed ID: 17668364
[TBL] [Abstract][Full Text] [Related]
4. Current perspective of HCV NS5B inhibitors: a review.
Patil VM; Gupta SP; Samanta S; Masand N
Curr Med Chem; 2011; 18(36):5564-97. PubMed ID: 22172066
[TBL] [Abstract][Full Text] [Related]
5. New NS5B polymerase inhibitors for hepatitis C.
Legrand-Abravanel F; Nicot F; Izopet J
Expert Opin Investig Drugs; 2010 Aug; 19(8):963-75. PubMed ID: 20629614
[TBL] [Abstract][Full Text] [Related]
6. NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B.
Bessa LM; Launay H; Dujardin M; Cantrelle FX; Lippens G; Landrieu I; Schneider R; Hanoulle X
J Biol Chem; 2017 Nov; 292(44):18024-18043. PubMed ID: 28912275
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase.
Wu JZ; Yao N; Walker M; Hong Z
Mini Rev Med Chem; 2005 Dec; 5(12):1103-12. PubMed ID: 16375756
[TBL] [Abstract][Full Text] [Related]
8. Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase.
Thueng-in K; Thanongsaksrikul J; Jittavisutthikul S; Seesuay W; Chulanetra M; Sakolvaree Y; Srimanote P; Chaicumpa W
MAbs; 2014; 6(5):1327-39. PubMed ID: 25517317
[TBL] [Abstract][Full Text] [Related]
9. Nucleoside analog inhibitors of hepatitis C virus replication.
Carroll SS; Olsen DB
Infect Disord Drug Targets; 2006 Mar; 6(1):17-29. PubMed ID: 16787301
[TBL] [Abstract][Full Text] [Related]
10. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.
Kukolj G; McGibbon GA; McKercher G; Marquis M; Lefèbvre S; Thauvette L; Gauthier J; Goulet S; Poupart MA; Beaulieu PL
J Biol Chem; 2005 Nov; 280(47):39260-7. PubMed ID: 16188890
[TBL] [Abstract][Full Text] [Related]
11. The discovery of finger loop inhibitors of the hepatitis C virus NS5B polymerase: status and prospects for novel HCV therapeutics.
Beaulieu PL
IDrugs; 2006 Jan; 9(1):39-43. PubMed ID: 16374732
[TBL] [Abstract][Full Text] [Related]
12. Dual Allosteric Inhibitors Jointly Modulate Protein Structure and Dynamics in the Hepatitis C Virus Polymerase.
Brown JA; Thorpe IF
Biochemistry; 2015 Jul; 54(26):4131-41. PubMed ID: 26066778
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of a benzodiazepine scaffold yields a potent allosteric inhibitor of hepatitis C NS5B RNA polymerase.
Vandyck K; Cummings MD; Nyanguile O; Boutton CW; Vendeville S; McGowan D; Devogelaere B; Amssoms K; Last S; Rombauts K; Tahri A; Lory P; Hu L; Beauchamp DA; Simmen K; Raboisson P
J Med Chem; 2009 Jul; 52(14):4099-102. PubMed ID: 19507864
[TBL] [Abstract][Full Text] [Related]
14. Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors.
Elhefnawi M; ElGamacy M; Fares M
BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S5. PubMed ID: 23282180
[TBL] [Abstract][Full Text] [Related]
15. 1,5-benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors.
Nyanguile O; Pauwels F; Van den Broeck W; Boutton CW; Quirynen L; Ivens T; van der Helm L; Vandercruyssen G; Mostmans W; Delouvroy F; Dehertogh P; Cummings MD; Bonfanti JF; Simmen KA; Raboisson P
Antimicrob Agents Chemother; 2008 Dec; 52(12):4420-31. PubMed ID: 18852280
[TBL] [Abstract][Full Text] [Related]
16. Preparation and biological evaluation of 1'-cyano-2'-C-methyl pyrimidine nucleosides as HCV NS5B polymerase inhibitors.
Mish MR; Cho A; Kirschberg T; Xu J; Zonte CS; Fenaux M; Park Y; Babusis D; Feng JY; Ray AS; Kim CU
Bioorg Med Chem Lett; 2014 Jul; 24(14):3092-5. PubMed ID: 24907145
[TBL] [Abstract][Full Text] [Related]
17. Ligand-induced changes in hepatitis C virus NS5B polymerase structure.
Rigat K; Wang Y; Hudyma TW; Ding M; Zheng X; Gentles RG; Beno BR; Gao M; Roberts SB
Antiviral Res; 2010 Nov; 88(2):197-206. PubMed ID: 20813137
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation.
Ryu K; Kim ND; Choi SI; Han CK; Yoon JH; No KT; Kim KH; Seong BL
Bioorg Med Chem; 2009 Apr; 17(8):2975-82. PubMed ID: 19332375
[TBL] [Abstract][Full Text] [Related]
19. Characterization of interactions between hepatitis C virus NS5B polymerase, annexin A2 and RNA - effects on NS5B catalysis and allosteric inhibition.
Solbak SMØ; Abdurakhmanov E; Vedeler A; Danielson UH
Virol J; 2017 Dec; 14(1):236. PubMed ID: 29228983
[TBL] [Abstract][Full Text] [Related]
20. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
Lemm JA; Liu M; Gentles RG; Ding M; Voss S; Pelosi LA; Wang YK; Rigat KL; Mosure KW; Bender JA; Knipe JO; Colonno R; Meanwell NA; Kadow JF; Santone KS; Roberts SB; Gao M
Antimicrob Agents Chemother; 2014 Jun; 58(6):3485-95. PubMed ID: 24733465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
